JP2011529964A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529964A5 JP2011529964A5 JP2011522114A JP2011522114A JP2011529964A5 JP 2011529964 A5 JP2011529964 A5 JP 2011529964A5 JP 2011522114 A JP2011522114 A JP 2011522114A JP 2011522114 A JP2011522114 A JP 2011522114A JP 2011529964 A5 JP2011529964 A5 JP 2011529964A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- alkynyl
- heteroaryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 40
- -1 cycloalkenylalkyl Chemical group 0.000 claims description 33
- 125000000623 heterocyclic group Chemical group 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 150000002148 esters Chemical class 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 14
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000000813 microbial effect Effects 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 8
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 108010003026 UDP-3-O-acyl-N-acetylglucosamine deacetylase Proteins 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- QUJXIMWUJGTUEG-CLKUPZDLSA-N 2-[2-[[[(2s,6s,9e,13s)-13-amino-2-[(4-hydroxyphenyl)methyl]-4,14-dioxo-1,5-diazacyclotetradec-9-ene-6-carbonyl]amino]methyl]phenyl]acetic acid Chemical compound C([C@H]1CC(=O)N[C@@H](CC/C=C/CC[C@@H](C(N1)=O)N)C(=O)NCC=1C(=CC=CC=1)CC(O)=O)C1=CC=C(O)C=C1 QUJXIMWUJGTUEG-CLKUPZDLSA-N 0.000 claims description 2
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 241000192125 Firmicutes Species 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 2
- 125000005020 hydroxyalkenyl group Chemical group 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000004385 trihaloalkyl group Chemical group 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 0 CC(C)(*(C(NO)O)NC(CCCN(CC*)C(C=C1)=CCC1=*(CC1)CCC1N1CCNCC1)=O)O Chemical compound CC(C)(*(C(NO)O)NC(CCCN(CC*)C(C=C1)=CCC1=*(CC1)CCC1N1CCNCC1)=O)O 0.000 description 3
- RTOGLJIVQSFYJY-UHFFFAOYSA-N C(CC1)CCN1C(CC1)C=CC1C#CC(CC1)C=CC1N1CCNCC1 Chemical compound C(CC1)CCN1C(CC1)C=CC1C#CC(CC1)C=CC1N1CCNCC1 RTOGLJIVQSFYJY-UHFFFAOYSA-N 0.000 description 1
- ZUGMNMDCFQYIBT-UHFFFAOYSA-N CC(C)(CNC(N(CC1)CCN1C(CC1)=CC=C1C1=CCCCC1)=O)C1CC1 Chemical compound CC(C)(CNC(N(CC1)CCN1C(CC1)=CC=C1C1=CCCCC1)=O)C1CC1 ZUGMNMDCFQYIBT-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8598208P | 2008-08-04 | 2008-08-04 | |
| US61/085,982 | 2008-08-04 | ||
| PCT/US2009/051898 WO2010017060A1 (en) | 2008-08-04 | 2009-07-28 | Urea derivatives as antibacterial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529964A JP2011529964A (ja) | 2011-12-15 |
| JP2011529964A5 true JP2011529964A5 (https=) | 2012-08-30 |
Family
ID=41171285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011522114A Pending JP2011529964A (ja) | 2008-08-04 | 2009-07-28 | 抗菌剤としての尿素誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110212080A1 (https=) |
| EP (1) | EP2315746A1 (https=) |
| JP (1) | JP2011529964A (https=) |
| AU (1) | AU2009279949A1 (https=) |
| CA (1) | CA2732045A1 (https=) |
| WO (1) | WO2010017060A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI519508B (zh) | 2007-06-12 | 2016-02-01 | Achaogen Inc | 抗菌劑 |
| JP5524215B2 (ja) | 2008-09-19 | 2014-06-18 | ファイザー・インク | 抗菌剤として有用なヒドロキサム酸誘導体 |
| WO2011073845A1 (en) | 2009-12-16 | 2011-06-23 | Pfizer Inc. | N-linked hydroxamic acid derivatives useful as antibacterial agents |
| WO2011132712A1 (ja) | 2010-04-20 | 2011-10-27 | 大正製薬株式会社 | 新規なヒドロキサム酸誘導体 |
| WO2012031298A2 (en) | 2010-09-03 | 2012-03-08 | Duke University | Ethynylbenzene derivatives |
| ES2626457T3 (es) | 2011-03-07 | 2017-07-25 | Pfizer Inc. | Derivados de fluoro-piridinona útiles como agentes antibacterianos |
| CA2830866A1 (en) | 2011-04-08 | 2012-10-11 | Pfizer Inc. | Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents |
| ES2526687T3 (es) | 2011-04-08 | 2015-01-14 | Pfizer Inc. | Derivados de isoxazol útiles como agentes antibacterianos |
| JP6006609B2 (ja) * | 2011-10-19 | 2016-10-12 | 大正製薬株式会社 | 新規なヒドロキサム酸誘導体を含有する医薬 |
| EP2847168A1 (en) | 2012-05-10 | 2015-03-18 | Achaogen, Inc. | Antibacterial agents |
| WO2014165075A1 (en) | 2013-03-12 | 2014-10-09 | Achaogen, Inc. | Antibacterial agents |
| DK2975022T3 (da) | 2013-03-15 | 2019-07-15 | Fujifilm Toyama Chemical Co Ltd | Hidtil ukendt hydroxaminsyrederivat eller salt deraf |
| WO2015024016A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | 2-piperidinyl substituted n,3-dihydroxybutanamides |
| US10647664B2 (en) | 2013-08-16 | 2020-05-12 | Duke University | Substituted hydroxamic acid compounds |
| WO2015024021A2 (en) | 2013-08-16 | 2015-02-19 | Duke University | Antibacterial compounds |
| JPWO2016039432A1 (ja) | 2014-09-12 | 2017-06-22 | 富山化学工業株式会社 | 新規なヒドロキサム酸誘導体および抗菌性物質を組み合わせて使用する方法 |
| BR112017004798A2 (pt) | 2014-09-12 | 2017-12-12 | Toyama Chemical Co Ltd | composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| AR108864A1 (es) | 2016-06-23 | 2018-10-03 | Achaogen Inc | Agentes antibacterianos |
| EP4219709A1 (en) | 2016-11-03 | 2023-08-02 | Temple University - Of The Commonwealth System of Higher Education | Dna plasmids for the fast generation of homologous recombination vectors for cell line development |
| BR112020016270A2 (pt) * | 2018-02-10 | 2020-12-15 | Kbp Biosciences Co., Ltd. | Composto atuando como antibióticos |
| CN115232130B (zh) * | 2021-04-22 | 2024-01-12 | 山东大学 | 一种apn和akt双靶点抑制剂及其制备方法和应用 |
| WO2023011573A1 (zh) * | 2021-08-05 | 2023-02-09 | 浙江海正药业股份有限公司 | 芳香乙炔类衍生物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925659A (en) * | 1996-05-07 | 1999-07-20 | Merck & Co., Inc. | Antibacterial agents |
| US6852752B2 (en) * | 1999-12-17 | 2005-02-08 | Vicuron Pharmaceuticals Inc. | Urea compounds, compositions and methods of use and preparation |
| EP1406893B1 (en) * | 2001-06-15 | 2007-04-18 | Vicuron Pharmaceuticals, Inc. | Pyrrolidine bicyclic compounds |
| KR101076018B1 (ko) * | 2003-01-08 | 2011-10-21 | 유니버시티 오브 워싱톤 | 항균제 |
| AU2007268507B2 (en) * | 2006-05-31 | 2012-01-19 | Daiichi Sankyo Company, Limited | Seven-membered ring compound, production method thereof and pharmaceutical use thereof |
-
2009
- 2009-07-28 WO PCT/US2009/051898 patent/WO2010017060A1/en not_active Ceased
- 2009-07-28 EP EP09790866A patent/EP2315746A1/en not_active Withdrawn
- 2009-07-28 JP JP2011522114A patent/JP2011529964A/ja active Pending
- 2009-07-28 CA CA2732045A patent/CA2732045A1/en not_active Abandoned
- 2009-07-28 US US13/057,505 patent/US20110212080A1/en not_active Abandoned
- 2009-07-28 AU AU2009279949A patent/AU2009279949A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529964A5 (https=) | ||
| JP2011525927A5 (https=) | ||
| KR102061137B1 (ko) | 금속효소 억제제 화합물 | |
| JP2020526561A5 (https=) | ||
| JP5535941B2 (ja) | 殺菌性アミド | |
| EP3119755B1 (en) | Antifungal compound process | |
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| EA036098B1 (ru) | Способ получения противогрибковых соединений | |
| EP3119764B1 (en) | Antifungal compound process | |
| JP2011520969A5 (https=) | ||
| CA2683696A1 (en) | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity | |
| JP2017533968A5 (https=) | ||
| JP2010506854A5 (https=) | ||
| JP2020517707A5 (https=) | ||
| CN102421756A (zh) | 杀真菌的吡唑化合物 | |
| JP2014520809A5 (https=) | ||
| JP2013528652A5 (https=) | ||
| JP2020527173A5 (https=) | ||
| JP2014532730A5 (ja) | オピオイド受容体の調節物質およびそれを含む薬学的組成物 | |
| CA2796877A1 (en) | Novel beta 3 adrenergic receptor agonists | |
| JP2017509644A (ja) | 抗真菌化合物の調製方法 | |
| JP2015536997A5 (https=) | ||
| TW200738698A (en) | Organic compounds | |
| CN110225781A (zh) | 噻唑衍生物及其应用 | |
| JP2018530582A5 (https=) |